NovoCure Limited Announces Launch of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
NovoCure Limited (NVCR) IPO Opens Lower
October 2, 2015 10:43 AM EDTToday's IPO for NovoCure Limited (Nasdaq: NVCR) opened for trading at $20.16 after pricing 12,500,000 shares of its common stock at $22, below the $23-$24 revised IPO range. Shares last traded at $19.
J.P. Morgan Securities LLC, Deutsche Bank Securities and Evercore Group... More
NovoCure (NVCR) Launches 12.5M Common Stock IPO
October 2, 2015 6:09 AM EDTNovoCure Limited (Nasdaq: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by NovoCure Limited and 5,000,000 shares to be sold by selling shareholders. The initial public offer is currently expected to be between $26 and $29 per share. The underwriters for the offering will... More
